1.11
+0.1833(+19.82%)
Currency In USD
| Previous Close | 0.93 |
| Open | 1.32 |
| Day High | 1.72 |
| Day Low | 1 |
| 52-Week High | 20.6 |
| 52-Week Low | 0.61 |
| Volume | 158.62M |
| Average Volume | 4.57M |
| Market Cap | 7.78M |
| PE | -0.2 |
| EPS | -5.64 |
| Moving Average 50 Days | 2.09 |
| Moving Average 200 Days | 5.59 |
| Change | 0.18 |
If you invested $1000 in KALA BIO, Inc. (KALA) since IPO date, it would be worth $1 as of December 04, 2025 at a share price of $0.925. Whereas If you bought $1000 worth of KALA BIO, Inc. (KALA) shares 5 years ago, it would be worth $2.49 as of December 04, 2025 at a share price of $0.925.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
GlobeNewswire Inc.
46 minutes ago
ARLINGTON, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA) (“KALA” or the “Company”), today announced that it has entered into definitive agreements for the purchase of an aggregate of 10,000,000 shares of its common stock (or
KALA BIO Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
GlobeNewswire Inc.
Dec 01, 2025 12:00 PM GMT
Investment to support the continued evaluation and redevelopment of KALA’s product candidates and patent portfolio, and provide working capital and funding for a potential future strategic transactionARLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE)
KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint
GlobeNewswire Inc.
Sep 29, 2025 12:00 PM GMT
-- Study did not meet primary endpoint of complete healing of PCED at Week 8; secondary endpoints also did not achieve statistical significance -- -- KPI-012 was well-tolerated with no treatment-related serious adverse events observed -- -- KALA to c